Acute lung damage is one of the most common types of serious sickness, and despite its high death rate and rapid progression, there is presently no clinically eective treatment for it. he significance of gene therapy in acute lung inury has gron over time as our understanding of the diseases pathological mechanism has deepened. ene therapy for acute lung inury no focuses mostly on improving alveolar fluid clearance, reducing pro-inflammatory response, and mending lung barrier. iral and non-viral vectors are currently used as gene delivery vehicles. hough less efficient than viral vectors, non-viral delivery technologies have the advantages of being less immunogenic, more aordable, and easier to mass-produce. here has been a great deal of research into non-viral delivery systems for gene therapy, including those based on lipids, dendrimers, polymers, graphene, and other inorganic nanoparticles. Exosomes and cells have been suggested as an alternative as a possible delivery techniue employed by nature to convey genes into the lungs. he revie uickly covers the development of gene therapy using non-viral vectors for the treatment of acute lung damage. he difficulties and possibilities that lie ahead for putting this approach into clinical practice are examined in order to give a full vie on gene therapy of acute lung damage
